Acuta Capital Partners’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-44,820
| Closed | -$1.6M | – | 39 |
|
|
2024
Q4 | $1.6M | Sell |
44,820
-3,180
| -7% | -$114K | 1.61% | 21 |
|
|
2024
Q3 | $2.27M | Sell |
48,000
-18,520
| -28% | -$875K | 1.84% | 19 |
|
|
2024
Q2 | $3.34M | Sell |
66,520
-20,065
| -23% | -$1.01M | 2.82% | 15 |
|
|
2024
Q1 | $9.7M | Sell |
86,585
-8,135
| -9% | -$911K | 6.3% | 3 |
|
|
2023
Q4 | $5.49M | Buy |
94,720
+90,736
| +2,278% | +$5.26M | 3.09% | 14 |
|
|
2023
Q3 | $127K | Buy |
+3,984
| New | +$127K | 0.08% | 40 |
|
|
2023
Q2 | – | Sell |
-2,400
| Closed | -$247K | – | 39 |
|
|
2023
Q1 | $247K | Sell |
2,400
-35,600
| -94% | -$3.66M | 0.18% | 28 |
|
|
2022
Q4 | $5.57M | Buy |
+38,000
| New | +$5.57M | 3.43% | 13 |
|
|
2021
Q2 | – | Sell |
-14,308
| Closed | -$5.79M | – | 44 |
|
|
2021
Q1 | $5.79M | Sell |
14,308
-13,452
| -48% | -$5.44M | 2.09% | 20 |
|
|
2020
Q4 | $18.5M | Buy |
27,760
+1,060
| +4% | +$705K | 5.03% | 5 |
|
|
2020
Q3 | $12.4M | Buy |
26,700
+1,400
| +6% | +$652K | 3.38% | 7 |
|
|
2020
Q2 | $14.8M | Sell |
25,300
-7,800
| -24% | -$4.56M | 4.28% | 5 |
|
|
2020
Q1 | $4.82M | Buy |
+33,100
| New | +$4.82M | 2.34% | 17 |
|